Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.
暂无分享,去创建一个
K. Rezvani | D. Marin | S. Parmar | E. Shpall | B. Andersson | B. Valdez | Y. Nieto | U. Popat | Q. Bashir | M. Qazilbash | A. Alousi | R. Champlin | R. Bassett | J. Kawedia | Roy B. Jones | P. Anderlini | R. Mehta | C. Hosing | P. Kebriaei | I. Khouri | B. Oran | S. Ciurea | N. Shah | Julianne J Chen | A. Olson | Jin S Im | S. Srour | S. Ahmed | G. Al-Atrash | Saira S. Ahmed